Arrowhead Pharmaceuticals, Inc.
ARWR
$79.04
$1.301.67%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -300.91M | 202.27M | -1.63M | -148.42M | -143.97M |
| Total Depreciation and Amortization | 25.37M | 25.08M | 23.93M | 22.57M | 21.13M |
| Total Amortization of Deferred Charges | 657.00K | -- | -- | -- | -- |
| Total Other Non-Cash Items | 168.54M | 184.55M | 175.49M | 119.62M | 113.31M |
| Change in Net Operating Assets | 70.04M | -72.59M | -18.24M | 28.08M | 70.68M |
| Cash from Operations | -36.31M | 339.31M | 179.55M | 21.85M | 61.15M |
| Capital Expenditure | -14.57M | -17.30M | -22.67M | -39.47M | -51.55M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -689.45M | -212.65M | -106.63M | -385.37M | -507.73M |
| Cash from Investing | -704.02M | -229.95M | -129.29M | -424.84M | -559.28M |
| Total Debt Issued | 710.26M | 10.26M | 10.26M | 399.10M | 392.00M |
| Total Debt Repaid | -134.51M | -268.31M | -201.63M | -201.63M | -151.63M |
| Issuance of Common Stock | 189.03M | 296.67M | 245.37M | 245.09M | 245.25M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -22.83M | 0.00 | 20.00M | 16.87M | 66.87M |
| Cash from Financing | 741.96M | 38.62M | 74.01M | 459.43M | 552.49M |
| Foreign Exchange rate Adjustments | 1.17M | -227.00K | -401.00K | 3.96M | 3.64M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.81M | 147.75M | 123.86M | 60.39M | 58.01M |